3天持续静脉泵注重组人血管内皮抑制素联合方案治疗实体瘤的不良反应观察与分析  

Adverse reactions observation and analysis on three days continuous intravenous pumping of rh-endostatin combined regimens for solid tumor treatment

作　　者：宋佶芳 彭红 彭兴巧 吴秀丽 蹇丹 蒲瑜 罗皓 赵亮 陈骞 钟力 王东 刘芳静 冯燕 SONG Jifang;PENG Hong;PENG Xingqiao;WU Xiuli;JIAN Dan;PU Yu;LUO Hao;ZHAO Liang;CHEN Qian;ZHONG Li;WANG Dong;LIU Fangjing;FENG Yan(Department of Oncology,Army Medical Center of PLA,Chongqing 400042,China)

机构地区：[1]陆军军医大学大坪医院肿瘤科,重庆400042

出　　处：《癌症进展》2021年第11期1132-1136,共5页Oncology Progress

摘　　要：目的观察与评估3天持续静脉泵注重组人血管内皮抑制素联合方案治疗实体瘤期间不良反应的发生情况。方法设计不良反应观察与记录表格,对接受3天持续静脉泵注重组人血管内皮抑制素联合方案治疗的127例实体瘤患者治疗期间的不良反应进行观察与记录,计算不良反应发生率。结果127例实体瘤患者中,92例(72.44%)接受重组人血管内皮抑制素联合化疗方案,26例(20.47%)接受重组人血管内皮抑制素联合化疗+程序性死亡受体1(PD-1)单抗方案,4例(3.15%)接受重组人血管内皮抑制素单药方案,5例(3.94%)接受重组人血管内皮抑制素联合PD-1单抗方案。血液学不良反应发生率为21.26%(27例),其中白细胞减少3.94%(5例),血小板减少2.36%(3例),贫血14.96%(19例);非血液学不良反应发生率为59.06%(75例),其中心肌酶异常3.15%(4例),心悸1.57%(2例),出血3.15%(4例),转氨酶异常22.05%(28例),肾功能异常6.30%(8例)。3级血液学不良反应发生率为2.36%(3例),2级和3级转氨酶异常发生率分别为7.87%(10例)和1.57%(2例)。结论3天持续静脉泵注重组人血管内皮抑制素联合治疗方案,不良反应可控,安全性可接受。非预期的转氨酶异常与3天持续静脉泵注重组人血管内皮抑制素的相关性需进一步评估。Objective To observe and evaluate the adverse reactions during three day of continuous intravenous pumping of rh-endostatin combined regimens for solid tumor treatment.Method The form for observation and record of adverse reactions was designed.The adverse reactions in 127 patients with solid tumor were observed and recorded during three day of continuous intravenous pumping of rh-endostatin combined regimens.The incidence of adverse reactions was calculated.Result Among 127 solid tumor patients,92 cases(72.44%)received rh-endostatin combined with chemotherapy,26 cases(20.47%)received rh-endostatin combined with chemotherapy+programmed cell death 1(PD-1)monoclonal antibody,and 4 cases(3.15%)received rh-endostatin monotherapy,5 cases(3.94%)received rh-endostatin combined with PD-1 monoclonal antibody,respectively.The rate of hematological toxicity was 21.26%(27 cases),among them,leukopenia 3.94%(5 cases),thrombocytopenia 2.36%(3 cases)and anemia 14.96%(19 cases);non-hematological toxicity 59.06%(75 cases),of them,myocardial enzyme abnormal 3.15%(4 cases),palpitation 1.57%(2 cases),bleeding 3.15%(4 cases),transaminase abnormal 22.05%(28 cases),renal dysfunction 6.30%(8 cases).The incidence of grade 3 hematological toxicity was 2.36%(3 cases)and grade 2 or 3 transaminase abnormal were 7.87%(10 cases)and 1.57%(2 cases),respectively.Conclusion Adverse reactions were controllable and acceptable during three day of continuous intravenous pumping of rh-endostatin combined regimens for tumor treatment.The unexpected transaminase abnormal warrant further investigation on the relation to continuous intravenous pumping of rh-endostatin.

关 键 词：实体瘤 重组人血管内皮抑制素 持续静脉泵注 不良反应 

分 类 号：R730.5[医药卫生—肿瘤]